<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120988</url>
  </required_header>
  <id_info>
    <org_study_id>RSI2015-LAB03</org_study_id>
    <nct_id>NCT03120988</nct_id>
  </id_info>
  <brief_title>Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage</brief_title>
  <acronym>PPP</acronym>
  <official_title>Assessing Catabolic Marker Levels in the Knee Synovial Fluid Microenvironment After Lavage With Platelet Poor Plasma (PPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenerative Sciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenerative Sciences, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how the components of osteoarthritic knee joint
      fluid (synovial fluid) change after lavage treatment with platelet poor plasma. Additionally,
      the study participants will complete outcome questionnaire surveys before and after the
      treatment in conjunction with when synovial fluid is removed from the knee (2, 4, and 6 weeks
      after lavage). This data will help determine if the treatment of an osteoarthritic knee joint
      with platelet poor plasma lavage is a suitable stand-alone therapy or to improve outcome by
      preparing a patient's knee for further regenerative therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to quantify the levels of catabolic markers in osteoarthritic
      (OA) knee synovial fluid microenvironment (ME) before lavage treatment with platelet poor
      plasma (PPP) and to determine whether the anti-catabolic capabilities of the PPP are
      sustainable or if the diseased synovial fluid returns to pre-lavage catabolic marker levels
      within the 6 week period of the study.

      This data will be used to determine if treatment of a diseased (OA) knee with PPP lavage
      would be a suitable therapy for knee OA patients either as a stand-alone treatment or to
      improve outcome by preparing a patient's knee microenvironment for further treatment with
      cellular therapies. Incidence of post-operative complications, adverse events, re-injections,
      and surgical intervention; change in pain score will be considered while determining these
      direct and indirect associations upon completion of the PPP lavage treatment. Correlation of
      subject reported clinical outcomes for the PPP lavage treatment will be evaluated to
      determine whether the treatment provides beneficial clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Lavage with platelet poor plasma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean temporal biomarkers (pg/ml)</measure>
    <time_frame>4 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Scales</measure>
    <time_frame>2, 4 and 6 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean International Knee Documentation Committee Subjective Knee Evaluation</measure>
    <time_frame>2, 4 and 6 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications and adverse events</measure>
    <time_frame>2, 4 and 6 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean temporal biomarkers (pg/ml)</measure>
    <time_frame>2 and 6 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Lavage with Platelet Poor Plasma (PPP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect &quot;washing out&quot; the joint space.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lavage with Platelet Poor Plasma (PPP)</intervention_name>
    <description>Lavage of 50cc PPP</description>
    <arm_group_label>Lavage with Platelet Poor Plasma (PPP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Voluntary signature of the institutional review board approved Informed Consent

          -  2) Male or female ages 35-85

          -  3) Pain, swelling, and/or functional disability in the affected knee consistent with
             osteoarthritis in the knee joint

          -  4) Physical examination consistent with osteoarthritis as observed on imaging

          -  5) Unilateral or bilateral Kellgren-Lawrence grade 3 or greater knee osteoarthritis
             (moderate to severe OA) and/or diagnostic MRI imaging of the affected knee showing
             osteoarthritis (i.e. chondral loss, fissuring, defect, bone marrow lesion, meniscus
             tear, synovial thickening, etcâ€¦)

          -  6) Mild effusion upon ultrasound evaluation.

          -  7) Is independent, ambulatory, and can comply with all postoperative evaluations and
             visits

        Exclusion Criteria:

          -  1) Knee injections of any type within 3 months prior to the study.

          -  2) Knee surgery within 6 months prior to the study.

          -  3) Inflammatory or auto-immune based joint diseases or other lower extremity pathology
             (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis,
             polymyalgia, polymyositis, gout pseudogout)

          -  4) Quinolone or Statin induced myopathy/tendinopathy

          -  5) Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh

          -  6) Contraindications for MRI

          -  7) Condition represents a worker's compensation case

          -  8) Currently involved in a health-related litigation procedure

          -  9) Is pregnant

          -  10) Bleeding disorders

          -  11) Currently taking anticoagulant or immunosuppressive medication

          -  12)Allergy or intolerance to study medication

          -  13)Use of chronic opioid

          -  14)Documented history of drug abuse within six months of treatment

          -  15)Any other condition, that in the opinion of the investigator, that would preclude
             the patient from enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Centeno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regenexx and Centeno-Schultz Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centeno-Schultz Clinic</name>
      <address>
        <city>Broomfield</city>
        <state>Colorado</state>
        <zip>80021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation--United States, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):869-73.</citation>
    <PMID>24196662</PMID>
  </reference>
  <reference>
    <citation>Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176.</citation>
    <PMID>18163497</PMID>
  </reference>
  <reference>
    <citation>Waimann CA, Fernandez-Mazarambroz RJ, Cantor SB, Lopez-Olivo MA, Zhang H, Landon GC, Siff SJ, Suarez-Almazor ME. Cost-effectiveness of total knee replacement: a prospective cohort study. Arthritis Care Res (Hoboken). 2014 Apr;66(4):592-9. doi: 10.1002/acr.22186.</citation>
    <PMID>24124052</PMID>
  </reference>
  <reference>
    <citation>Katz JN, Brophy RH, Chaisson CE, de Chaves L, Cole BJ, Dahm DL, Donnell-Fink LA, Guermazi A, Haas AK, Jones MH, Levy BA, Mandl LA, Martin SD, Marx RG, Miniaci A, Matava MJ, Palmisano J, Reinke EK, Richardson BE, Rome BN, Safran-Norton CE, Skoniecki DJ, Solomon DH, Smith MV, Spindler KP, Stuart MJ, Wright J, Wright RW, Losina E. Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med. 2013 May 2;368(18):1675-84. doi: 10.1056/NEJMoa1301408. Epub 2013 Mar 18. Erratum in: N Engl J Med. 2013 Aug 15;369(7):683.</citation>
    <PMID>23506518</PMID>
  </reference>
  <reference>
    <citation>Getgood A, Collins B, Slynarski K, Kurowska E, Parker D, Engebretsen L, MacDonald PB, Litchfield R. Short-term safety and efficacy of a novel high tibial osteotomy system: a case controlled study. Knee Surg Sports Traumatol Arthrosc. 2013 Jan;21(1):260-9. doi: 10.1007/s00167-011-1709-4. Epub 2011 Oct 18.</citation>
    <PMID>22005964</PMID>
  </reference>
  <reference>
    <citation>Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011 Sep;23(5):471-8. doi: 10.1097/BOR.0b013e328349c2b1. Review.</citation>
    <PMID>21788902</PMID>
  </reference>
  <reference>
    <citation>Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q, Terek R, Fleming BC, Goldring MB, Ehrlich MG, Zhang G, Wei L. Identification of Î±2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014 Jul;66(7):1843-53. doi: 10.1002/art.38576.</citation>
    <PMID>24578232</PMID>
  </reference>
  <reference>
    <citation>Rehman AA, Ahsan H, Khan FH. Î±-2-Macroglobulin: a physiological guardian. J Cell Physiol. 2013 Aug;228(8):1665-75. doi: 10.1002/jcp.24266. Review.</citation>
    <PMID>23086799</PMID>
  </reference>
  <reference>
    <citation>Irrgang JJ, Anderson AF, Boland AL, Harner CD, Neyret P, Richmond JC, Shelbourne KD; International Knee Documentation Committee. Responsiveness of the International Knee Documentation Committee Subjective Knee Form. Am J Sports Med. 2006 Oct;34(10):1567-73. Epub 2006 Jul 26.</citation>
    <PMID>16870824</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee OA</keyword>
  <keyword>lavage</keyword>
  <keyword>Platelet Poor Plasma (PPP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

